Blood Thinners and Macular Degeneration: Does Warfarin Raise the Odds of Turning Wet?
What the Research Actually Shows About Blood Thinners and Wet AMD
If you take a blood thinner like warfarin and you have macular degeneration, it is reasonable to wonder whether the medicine could push your dry AMD toward the more serious wet form. The honest answer is that the evidence is limited and mostly observational, so it can show links but not prove cause. Some studies have found that people taking warfarin convert from dry to wet AMD somewhat more often than people taking newer direct oral anticoagulants (DOACs), but researchers describe this as an association, not proof that warfarin causes the change1. What is not in doubt is that you should not stop a prescribed blood thinner on your own.
Two different questions get mixed together here, and separating them helps. First, do blood thinners make dry AMD more likely to turn wet in the first place? Second, if wet AMD does bleed, do blood thinners make that bleed worse? The clearer signal is on the second question: when a bleed under the macula (a submacular hemorrhage) happens in wet AMD, blood thinners are associated with a larger bleed, though not a more frequent one, and warfarin is associated with larger bleeds and worse vision than DOACs2. The first question, about causing the wet conversion itself, is much less settled.
Because the stakes of stopping a blood thinner are high, the most important point comes first. Experts advise that people told by their doctors to take a blood thinner should keep taking it, because the benefit of preventing strokes and clots outweighs the potential eye risk, and any change should be an individualized decision made with the prescribing doctor3. Stopping a blood thinner to protect your eyes could trade a small, unproven eye risk for a real and serious risk of stroke. The rest of this page explains what the studies found and how to think about them.
The Question, and the Terms Behind It
Most macular degeneration is the dry form, while wet AMD happens when abnormal, leaky blood vessels grow under the retina and can cause faster central vision loss4. 'Turning wet' is the shift from dry to wet AMD, and it is the change people worry about because it can move quickly. Wet AMD is treated with anti-VEGF injections, and its warning signs include straight lines starting to look wavy and new blank or dark spots in the center of vision4. The concern with blood thinners is not new blood vessels themselves but whether thinner blood makes those fragile vessels bleed more.
The word 'blood thinner' covers two different kinds of drug, and the distinction runs through this whole topic. Antiplatelet drugs such as aspirin work differently from anticoagulants such as warfarin and the direct oral anticoagulants (DOACs), and the studies find different risk patterns for each2. Warfarin is a vitamin K antagonist, an older anticoagulant; DOACs are a newer class. When you read that a study found a risk with 'warfarin' but not with 'aspirin,' that is not a contradiction; they are separate medicines doing separate jobs.
The worry is mechanically reasonable, which is why it has been studied. Wet AMD involves fragile new vessels that can leak or bleed, and a medicine that slows clotting could, in theory, let a small bleed become a larger one. This is why the strongest evidence concerns the size of a bleed once it occurs rather than whether the disease starts, and why blood thinners are linked to larger submacular hemorrhages in wet AMD2. A plausible mechanism is a good reason to study something carefully, but it is not the same as proof that the drug causes harm in practice.
What the Studies Have Found
Aspirin has been studied the most, and the results genuinely conflict. Some observational studies found that people who took aspirin at least weekly were about twice as likely as nonusers to develop wet AMD, although the absolute increase was small, on the order of about one extra case per 100 people3. However, a meta-analysis that pooled 10 studies covering 171,729 people found no overall association between aspirin and AMD, with a pooled relative risk of 1.09 (a confidence interval from 0.96 to 1.24 that includes no effect) and no significant link for either early or late AMD5. So the largest combined analysis is reassuring, even though individual studies have pointed both ways.
Warfarin is the drug in the question, and the most directly relevant study is recent. A 2024 retrospective study comparing about 13,000 warfarin users with about 20,000 DOAC users found that warfarin users had a higher rate of conversion from dry to wet AMD and more macular and vitreous hemorrhage and anti-VEGF treatment than DOAC users1. That sounds alarming, but two things temper it: it compares warfarin against another blood thinner rather than against no treatment, and it is observational, so people on warfarin may differ in other ways that affect the eye. The authors themselves framed the finding as an association and said any switch from warfarin to a DOAC must be considered carefully with the patient's other doctors1.
The most consistent finding is about severity, not frequency. In people with wet AMD who developed a submacular hemorrhage, blood thinners were associated with a larger bleed, about 36 versus 22 square millimeters, but were not associated with the bleed happening more often2. Within that group, warfarin was associated with substantially larger hemorrhages and worse vision than DOACs2. This is worth knowing, and it is also why the decision is a medical one: a larger potential bleed is weighed against the stroke or clot the blood thinner is preventing, which is a trade only your doctors can balance for you.
It is just as important to be clear about the limits. These studies are observational and compare groups of people who were already taking different drugs, so they can show that warfarin use and worse eye outcomes travel together but cannot prove that warfarin causes the wet conversion or the larger bleed1. People prescribed warfarin often have other health differences, such as heart rhythm problems, that could independently affect the eye. No study here tested stopping a blood thinner to protect vision, so there is no evidence that stopping helps, and good reason to think it would cause harm elsewhere.
How Strong Is This Evidence?
The honest grade on this evidence is modest. Almost all of the data linking specific blood thinners to wet AMD come from observational studies, which follow people already taking these drugs rather than randomly assigning them, so they are prone to confounding and can establish association but not causation1. The one high-quality tool available, the pooled meta-analysis of aspirin, actually found no overall effect. That combination, weak observational signals plus a reassuring pooled analysis, is why no professional body recommends stopping a blood thinner for AMD.
Different studies disagree, which is itself informative. One large observational study linked weekly aspirin to roughly double the odds of wet AMD, while a meta-analysis of 10 studies found no overall association at all5. And for bleeding, blood thinners were linked to a larger hemorrhage but not a more frequent one, a pattern that argues against a simple story of 'thinner blood causes more disease'2. When strong studies point in different directions, the responsible reading is caution about any single headline, not action on it.
The question would be answered by a randomized trial, and there is a reason none exists. It would be neither ethical nor safe to randomly take people off a blood thinner they medically need just to watch their eyes, so the field relies on observational data and careful comparisons between drug classes. Until better evidence exists, the practical guidance is to individualize the decision with the prescribing doctor rather than act on any one study3. That is not a dodge; it is the correct response to genuinely uncertain evidence in a high-stakes situation.
Weighing the Risks: Your Eyes Versus the Rest of You
Blood thinners are not prescribed lightly. They prevent strokes in people with atrial fibrillation, treat and prevent dangerous clots, and protect people after certain heart events. Because those benefits are large and well established, experts advise continuing a prescribed blood thinner rather than stopping it over a small and unproven AMD risk3. The realistic outlook is that the systemic protection is the bigger, better-proven benefit, and it is not worth trading for a theoretical eye gain.
Kept in proportion, the eye risk is modest and uncertain. Even in the studies that found a link, the absolute increase in wet AMD was small, and the pooled analysis found no overall increase, so this is a possible modest risk rather than a proven large one5. If a bleed does occur, blood thinners are linked to a larger one, but wet AMD is treatable with anti-VEGF injections, and catching a change early is what most protects vision4. So the eye risk is real enough to monitor for, not large enough to stop a needed medicine over.
For most people, the sensible path is steady monitoring, not medication changes. Keep taking your blood thinner as prescribed, keep your eye appointments, watch for the warning signs below, and let your doctors weigh any change together. If your doctors ever do consider adjusting your anticoagulation, one option they may discuss is whether a DOAC fits your situation better than warfarin, but that is their call to make with your full medical picture1. The outlook with this approach is good: the systemic risks stay covered, and any eye change gets caught while it is most treatable.
When to Call, and What Never to Do on Your Own
This is the single most important action point on the page. Do not stop or change a prescribed blood thinner because of AMD without talking to the doctor who prescribed it, because stopping can raise your risk of a stroke or a dangerous clot, and the AMD benefit of stopping is unproven3. If the possibility worries you, that worry is worth a conversation, not a unilateral decision. Bring it to your prescribing doctor and your eye doctor so they can weigh it together with everything else about your health.
Whether or not you take a blood thinner, certain vision changes deserve a prompt call to your eye doctor:
- New, painless distortion, where straight lines look wavy or bent, usually in one eye6
- A new or growing dark, gray, or blank spot in your central vision6
- A sudden drop or blur in central vision in one eye6
These can signal conversion to wet AMD, which develops over days to weeks and is best examined promptly, typically within about 24 hours of onset6. This is not a reason to panic: wet AMD is treatable, and prompt care is exactly what preserves vision.
Two doctors share this decision, and both should be in the loop. Decisions about blood thinners in someone with AMD are best made through communication between the prescribing doctor and the eye specialist rather than by either one alone2. Ongoing wet AMD care, including the anti-VEGF injections, is handled by a retina specialist, so ask to be referred if you are not already under one. Your prescribing doctor owns the blood thinner decision; your eye doctor owns the eye.
Common Questions About Blood Thinners and AMD
There is no proof that it does. A 2024 study found warfarin users converted to wet AMD somewhat more often than DOAC users, but this is an association from observational data, not proof of cause, and warfarin users often differ in other ways that affect the eye1. The safe reading is that a modest possible link exists but is unproven. That is a reason to monitor your vision and keep your eye appointments, not a reason to stop a medicine that may be preventing a stroke.
No, not on your own. Experts advise continuing a prescribed blood thinner, because the stroke and clot protection outweighs a small, unproven AMD risk, and any change should be individualized with your prescribing doctor3. No study has shown that stopping a blood thinner protects vision, and stopping carries a real risk of serious harm elsewhere. If you are worried, raise it with your doctors; they can weigh your specific risks far better than a general rule can.
The evidence treats them differently. A meta-analysis of 10 studies and 171,729 people found no overall association between aspirin and AMD, whereas the concern about larger bleeding and more conversion has centered on warfarin compared with newer DOACs5. So aspirin and warfarin should not be lumped together. Whichever you take, though, the same advice holds: keep taking it as prescribed and discuss any concern with your doctor rather than adjusting it yourself.
It may make the bleed larger, though not more likely. In wet AMD, blood thinners were associated with a larger submacular hemorrhage (about 36 versus 22 square millimeters) but not a more frequent one, and warfarin was linked to larger bleeds and worse vision than DOACs2. This is a real reason for your doctors to weigh the decision carefully, and also a reason to report vision changes promptly so treatment starts early. It is not a reason to stop the medicine, because the systemic risk of stopping remains.
It might be discussed, but it is a medical decision. Studies suggest DOACs are associated with smaller eye bleeds and less conversion than warfarin, and researchers say a switch could be considered carefully with the patient's other doctors, but the decision depends on your whole medical picture1. Warfarin is chosen over DOACs for good reasons in some people, such as certain heart valves. So this is a question to raise with your prescribing doctor, not a change to request or make on your own.
More Questions, and What to Ask Your Doctor
On its own, usually not. No professional body recommends stopping or avoiding a blood thinner because of AMD, because the evidence of eye harm is weak and observational while the benefit of the drug is well established3. AMD may be one more factor your doctors keep in mind, especially if you already have wet AMD or a history of bleeding, but it does not by itself override the reason the blood thinner was prescribed. The decision stays individualized and shared between your doctors.
Through regular exams and your own monitoring. Because wet AMD warning signs include new distortion and blank spots that can appear over days to weeks, your eye doctor will use dilated exams and imaging and may ask you to watch your central vision at home so any change is caught early6. Catching a conversion early is what makes anti-VEGF treatment most effective. If you take a blood thinner, tell your eye doctor, and tell your prescribing doctor about your AMD, so both have the full picture.
- Given my heart or clot risk, do the benefits of my blood thinner still clearly outweigh any eye concern?
- Is a DOAC an option for me instead of warfarin, or are there reasons warfarin is better for my situation?
- Do I have dry or wet AMD now, and does that change how we think about my blood thinner?
- What vision changes should make me call you right away?
- Can my prescribing doctor and eye doctor coordinate on this decision?
- Review of Optometry, reporting Alsoudi AF, Koo E, Wai K, et al., Ophthalmology 2024 (2024). Some Blood Thinners May Increase Conversion to Wet AMD.
- Graefe's Archive for Clinical and Experimental Ophthalmology (2022). Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration.
- American Academy of Ophthalmology (AAO) (2013). Does Taking Aspirin Raise Your Risk of AMD?.
- National Eye Institute (NEI) (2024). Age-Related Macular Degeneration (AMD).
- Zhu W, Wu Y, Xu D, et al., PLoS One (2013). Aspirin Use and Risk of Age-Related Macular Degeneration: A Meta-Analysis.
- Review of Optometry (Majcher OD, Petry OD, Das OD) (2022). Identifying Conversion to Wet AMD.